Agile Therapeutics Analyst Ratings
Agile Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 189.02% | Maxim Group | → $5 | Upgrades | Hold → Buy |
| 06/26/2023 | 593.64% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 06/07/2023 | 593.64% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 12/30/2022 | 73.41% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 07/26/2022 | -42.2% | Maxim Group | → $1 | Upgrades | Hold → Buy |
| 07/11/2022 | 189.02% | HC Wainwright & Co. | $2.5 → $5 | Maintains | Buy |
| 04/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 11/03/2021 | 44.51% | HC Wainwright & Co. | $3.5 → $2.5 | Maintains | Buy |
| 09/13/2021 | 102.31% | HC Wainwright & Co. | $7 → $3.5 | Maintains | Buy |
| 07/27/2021 | 189.02% | RBC Capital | $6 → $5 | Maintains | Outperform |
| 12/08/2020 | 304.62% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 03/20/2020 | 246.82% | HC Wainwright & Co. | $7 → $6 | Reiterates | → Buy |
| 02/18/2020 | 304.62% | HC Wainwright & Co. | $5 → $7 | Maintains | Buy |
| 02/18/2020 | 362.43% | RBC Capital | $5 → $8 | Maintains | Outperform |
| 06/07/2019 | 189.02% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
| 11/29/2018 | 73.41% | Maxim Group | → $3 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/22/2023 | 189.02% | Maxim 集團 | → 5 美元 | 升級 | 持有 → 買入 |
| 06/26/2023 | 593.64% | HC Wainwright & Co. | → 12 美元 | 重申 | 購買 → 購買 |
| 06/07/2023 | 593.64% | HC Wainwright & Co. | → 12 美元 | 重申 | 購買 → 購買 |
| 12/30/2022 | 73.41% | HC Wainwright & Co. | 5 美元 → 3 美元 | 維護 | 購買 |
| 07/26/2022 | -42.2% | Maxim 集團 | → 1 美元 | 升級 | 持有 → 買入 |
| 2022 年 11 月 7 日 | 189.02% | HC Wainwright & Co. | 2.5 美元 → 5 美元 | 維護 | 購買 |
| 04/08/2022 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 11/03/2021 | 44.51% | HC Wainwright & Co. | 3.5 美元 → 2.5 美元 | 維護 | 購買 |
| 09/13/2021 | 102.31% | HC Wainwright & Co. | 7 美元 → 3.5 美元 | 維護 | 購買 |
| 2021 年 7 月 27 日 | 189.02% | 加拿大皇家銀行資本 | 6 美元 → 5 美元 | 維護 | 跑贏大盤 |
| 12/08/2020 | 304.62% | HC Wainwright & Co. | 6 美元 → 7 美元 | 維護 | 購買 |
| 03/20/2020 | 246.82% | HC Wainwright & Co. | 7 美元 → 6 美元 | 重申 | → 購買 |
| 02/18/2020 | 304.62% | HC Wainwright & Co. | 5 美元 → 7 美元 | 維護 | 購買 |
| 02/18/2020 | 362.43% | 加拿大皇家銀行資本 | 5 美元 → 8 美元 | 維護 | 跑贏大盤 |
| 06/07/2019 | 189.02% | 奧本海默 | → 5 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 11/29/2018 | 73.41% | Maxim 集團 | → 3 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Agile Therapeutics (AGRX)?
Agile Therapeutics（AGRX）的目標價格是多少？
The latest price target for Agile Therapeutics (NASDAQ: AGRX) was reported by Maxim Group on September 22, 2023. The analyst firm set a price target for $5.00 expecting AGRX to rise to within 12 months (a possible 189.02% upside). 4 analyst firms have reported ratings in the last year.
Maxim集團於2023年9月22日公佈了Agile Therapeutics（納斯達克股票代碼：AGRX）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計AGRX將在12個月內上漲至189.02％（可能上漲189.02％）。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Agile Therapeutics (AGRX)?
Agile Therapeutics（AGRX）的最新分析師評級是多少？
The latest analyst rating for Agile Therapeutics (NASDAQ: AGRX) was provided by Maxim Group, and Agile Therapeutics upgraded their buy rating.
Agile Therapeutics（納斯達克股票代碼：AGRX）的最新分析師評級由Maxim集團提供，Agile Therapeutics上調了買入評級。
When is the next analyst rating going to be posted or updated for Agile Therapeutics (AGRX)?
Agile Therapeutics（AGRX）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agile Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agile Therapeutics was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Agile Therapeutics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Agile Therapeutics的最後一次評級是在2023年9月22日提交的，因此你應該預計下一個評級將在2024年9月22日左右公佈。
Is the Analyst Rating Agile Therapeutics (AGRX) correct?
分析師對敏捷療法（AGRX）的評級是否正確？
While ratings are subjective and will change, the latest Agile Therapeutics (AGRX) rating was a upgraded with a price target of $0.00 to $5.00. The current price Agile Therapeutics (AGRX) is trading at is $1.73, which is within the analyst's predicted range.
雖然評級是主觀的，並且會發生變化，但最新的敏捷療法（AGRX）評級已上調，目標股價爲0.00美元，至5.00美元。Agile Therapeutics（AGRX）目前的交易價格爲1.73美元，在分析師的預測區間內。